Ocuphire Pharma Inc
NASDAQ:OCUP
Ocuphire Pharma Inc
Total Current Liabilities
Ocuphire Pharma Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ocuphire Pharma Inc
NASDAQ:OCUP
|
Total Current Liabilities
$4.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$37B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$35.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
Ocuphire Pharma Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.
See Also
What is Ocuphire Pharma Inc's Total Current Liabilities?
Total Current Liabilities
4.2m
USD
Based on the financial report for Jun 30, 2024, Ocuphire Pharma Inc's Total Current Liabilities amounts to 4.2m USD.
What is Ocuphire Pharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
11%
Over the last year, the Total Current Liabilities growth was -27%. The average annual Total Current Liabilities growth rates for Ocuphire Pharma Inc have been 16% over the past three years , 3% over the past five years , and 11% over the past ten years .
